Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion

First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter

Moderna pauses plan to build mRNA manufacturing facility in Kenya

The demand in Africa for COVID-19 vaccines has declined

Croda and AAHI partner to drive innovation in vaccine development

The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development

Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development

The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility

Apotex to acquire Canadian Searchlight Pharma

Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals

Akums introduces Hydroxyurea oral suspension for sickle cell disease

This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India

Govt. announces the revamped pharmaceuticals technology upgradation assistance scheme

Industry’s reaction to Union Budget 2024-25

Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry

Mandaviya virtually launches 'MedTech Mitra'

MedTech Mitra is a platform that will help the young talents of the country by holding their hands and giving them final shape to their research, knowledge and logic

Pfizer expects 2024 revenue between US$ 58.5 to US$ 61.5 billion

Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid